Cell Type: hybridoma:lymphoblast B lymphocyte; somatic cell hybrid
Cellular Products:
immunoglobulin; monoclonal antibody; against a chlamydia genus antigen
Permits/Forms:
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:
Animals were immunized with C. trachomatis elementary bodies. Spleen cells were fused with Sp2/0-Ag14 myeloma cells.
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Temperature: 37.0°C
Subculturing:
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10(5) viable cells/ml. Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml. Attached cells may be subcultured by scraping. Medium Renewal: Every 2 to 3 days
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002 recommended serum:ATCC 30-2020
References:
40475: MacDonald B, et al. Oral vaccine comprising anti-idiotypic antibody to chlamydia glycolipid exoantigen and process. US Patent 5,656,271 dated Aug 12 1997